Achillion has drug candidates that are poised to meet patient needs
Achillion employs a rational, intensely iterative approach to drug discovery and development, while applying market insight throughout the process to identify the greatest patient and clinical needs, the most efficient development pathways, and the best commercial opportunities for its new medicines.
The result is a prolific and sustainable discovery engine for potent and specific small-molecule drug candidates that has already produced multiple agents with breakthrough potential for chronic hepatitis C (HCV) infection and complement-mediated diseases.
Achillion intends to develop and commercialize factor D inhibitors for rare diseases. Achillion has nominated ACH-4471 in 2015 and initiated clinical development in February 2016. Achillion also discovered and developed a comprehensive portfolio of antivirals for the treatment of hepatitis C (HCV), including a second-generation NS5A inhibitor, odalasvir (also known as ACH-3102), a novel nucleotide NS5B polymerase inhibitor, ACH-3422, and a NS3/4A protease inhibitor, sovaprevir. Achillion established a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the further development and commercialization of these compounds.
Odalasvir, ACH-3422 and sovaprevir are investigational compounds. Their safety and efficacy have not been established.